MedTrace Logo

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

NCT03779113 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2026-02-18

Study results available
· View outcomes & findings →

Summary

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

Conditions

  • Non Hodgkin Lymphoma

Interventions

DRUG

HMPL-523

Oral HMPL-523

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Michael Shi, MD · Hutchmed

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2025-02-26
Completion
2025-02-26
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • Finland
  • France
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03779113 on ClinicalTrials.gov